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Identity 
Other names: PORIN, VDAC-1 




The gene encompasses over 33 kb of DNA; 9 exons. 
Transcription 
There are 3 splice variants reported but they all encode 
the same 282 amino acids protein.  
One transcript variant has an mRNA product length of 
1993 bp (accession number: NM_003374). Processed 
length 852 bp. 
Protein 
Description 
Voltage-dependent anion-selective channel protein 1 
(VDAC1, accession number: NP_003365.1) encodes 
for a protein product length of 283. 
VDAC1 regulates the flux of mostly anionic 
metabolites through the outer mitochondrial membrane, 
which is highly permeable to small molecules.  
VDAC is the most abundant protein in the outer 
membrane.  
Changes in membrane potentials can switch VDAC 
between open or high-conducting and closed or low-
conducting forms. 
Expression 
Mitochondrial porins have been found in all eukaryotic 
cells studied to date.  
In mammalian tissues VDAC1 is expressed in many 
normal and tumour tissues.  
It has been well characterized in brain, heart, skeletal 
muscle, and liver.  
Human cancer cell lines express higher VDAC1 levels 
than normal cells (Shinohara et al., 2000; Sinamura et 
al., 2006; Sinamura et al., 2008). 
Localisation 
Primarily in the Outer Mitochondrial Membrane 
(OMM), but in erythrocytes cell death events 
(eryptosis) it has been found in the plasma membrane 
(Sridharan et al., 2012). 
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Schematic representation of VDAC1 inserted in the membrane. The image was prepared using the crystal structure of mouse 
VDAC1, PDB ID 3emn (PDB). 
 
Function 
VDAC1, located at the OMM, is a key protein in 
regulating the exchange of ions, nucleotides and a 
variety of metabolites in and out of the mitochondria. 
As such, VDAC1 serves a crucial role in cellular 
energy maintenance. It provides a permeation pathway 
for metabolites and mobile ions between the cytosol 
and mitochondria. VDACs are also involved in cell 
death by interacting with apoptotic proteins and 
releasing apoptotic metabolites to the cytosol. 
Protein modifications. VDAC1 has been shown to be 
phosphorylated in multiple sites: serine, threonine, and 
tyrosine. Some candidate kinases have been suggested: 
GSK3, CaM-II, CKI, PKA, PKC, cdc2, p38MAPK, 
Nek1, EGFR, and SRC. Following reconstitution of 
VDAC1 into planar lipid bilayers, phosphorylation by 
PKA reduces the channel current. In rat liver OMM the
N-terminal methionine from VDAC1 is removed and 
the new amino terminal alanine is acetylated. Two 
separate studies demonstrated that VDAC1 was 
multiply acetylated in mouse liver, each study reported 
different sites. VDAC1 is ubiquitinated following 
mitochondrial depolarization (Narendra et al., 2010). 
Protein interactions. Localization of VDAC1 to the 
OMM makes it a functional anchor point for molecules 
that interact with the mitochondria. VDAC1 displays 
binding sites for glycerol kinase, hexokinase (HK), 
creatine kinase, mitochondrial creatine kinase (MtCK) 
(interacts with VDAC1 competing with HK and Bax). 
VDAC also forms complexes with other proteins, such 
as the ANT, the peripheral benzodiazepine receptor 
(TSPO), tubulin, the dynein light chain, mtHSP70, the
ORDIC channel, glyceraldehyde 3-phosphate 
dehydrogenase, actin and gelsolin, as well as with 
apoptosis-regulating proteins, such as members of the 
Bcl-2 family. 
VDAC1 oligomerization. VDAC1 has been shown to  
 
assemble into dimers, trimers, tetramers, and higher 
oligomeric states in a dynamic process, including the 
VDAC1 purified from liver mitochondria, recombinant 
human VDAC, and liver or brain mitochondrion-
embedded VDAC1. The supramolecular organization 
of VDAC1 has also been demonstrated using Atomic 
Force Microscope. Oligomeric assembly of VDAC1 
has been shown to be coupled to apoptosis induction, 
with oligomerization increasing substantially upon 
apoptosis induction and inhibited by apoptosis 
blockers. 
N-terminal domain. The N-terminus of VDAC1 is 25 
amino acids long, and contains an alpha helix (betwe n 
residues 5-16). In recently published 3-D structures the 
N-terminus resides within the pore; independent studies 
show that it could move out of the pore. The N-
terminal α-helical segment is proposed to be involved 
in channel gating, where it could be acting as the 
voltage sensor and possibly regulating the conductance 
of ions and metabolites through the VDAC1 pore. 
VDAC1-N-terminus is required for apoptosis 
induction, its interaction with HK-I and Bcl2 has a 
protective effect against apoptosis (Arbel and Shoshan-
Barmatz, 2009). 
Homology 
In higher eukaryotes, three VDAC isoforms have been 
characterized: VDAC1, VDAC2 and VDAC3, encoded 
by three separate genes. VDACs are highly conserved 
across species. VDAC1 is the most abundant isoform in 
most cells, being ten times more prevalent than 
VDAC2 and 100 times more prevalent than VDAC3 in 
HeLa cells (De Pinto et al., 2010). Recently it was 
demonstrated that while VDAC1 and VDAC2 are 
localized mainly within the same distinct domains of 
the OMM, VDAC3 is mostly distributed uniformly 
over the surface of the mitochondrion. 
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Mutations 
Somatic 
Direct DNA sequencing of colorectal cancer (CRC) 
and gastric cancer (GC) led to identification of a 
recurrent VDAC1 mutation. This mutation, c.332delA, 
leads to a premature stop codon, resulting in truncation 
of the amino acid synthesis (p.Asn111MetfsX34) and 
would remove about 60% length of C-terminal VDAC1 
protein. The DNA sequencing indicated that the 
mutation was heterozygous. There was no significant 
difference of the mutations with respect to the 
clinicopathologic features of the GC and CRC (Fisher'  
exact test, p>0,05) (Yoo et al., 2011). 
Implicated in 
VDAC1 and cancer 
Note 
Hexokinase (HK) interacts with VDAC to mediate its 
anti-apoptotic activity. It has been reported that uman 
cancer cell lines express higher VDAC1 levels than 
normal cells, while mitochondria from malignant tumor 
cell lines are capable of higher HK binding, thus 
increasing protection against apoptosis. The HK-
VDAC interaction is thought to underlie cell survival 
and apoptosis regulation by HK.  
A) HK bound to VDAC on the mitochondrial surface 
provides metabolic benefit that offers the cell a 
proliferative advantage.  
B) HK-I and HK-II binding to VDAC1 protects against 
apoptosis, with their release enabling activation of 
apoptosis. 
C) HK was shown to reduce mitochondrial reactive 
oxygen species (ROS) generation through an ADP-
recycling mechanism. Accordingly, detachment of HK 
from VDAC1 could lead to increased H2O2 generation 
and release to the cytoplasm, thereby activating cell 
death. 
D) The interaction of HK with VDAC protects against 
activation of apoptosis by BCL2-associated X protein 
(Bax) or Bcl-2 homologous antagonist/killer (Bak). 
Thus, VDAC-bound HK renders cells much more 
resistant to apoptosis. 
Rare mitochondrial encephalomyopathy 
Note 
Tissue-specific VDAC isoform 1 (HVDAC1) 
deficiency in human skeletal muscle is responsible for a 
rare mitochondrial encephalomyopathy, fatal in 
childhood (Messina et al., 1999). 
Neurodegenerative diseases 
Note 
Protein level changes of VDAC1 in brain of patients 
with Alzheimer's disease and Down syndrome have 
been reported (Yoo et al., 2001). 
Although evidence supporting a role for VDAC in the 
pathogenesis of Alzheimer's disease (AD) exists, its 
precise contribution is unknown. It has been suggested 
that VDAC may be involved in membrane dysfunction 
associated with AD neuropathology. The extent of 
oxidative damage to VDAC was reflected in the 
increase in nitrated VDAC1 in AD. VDAC 
modifications may alter VDAC-mediated bidirectional 
energy fluxes across the mitochondrial membrane. 
VDAC has been studied in Down's syndrome patients, 
epilepsy animal models, in dopamine-induced 
apoptosis, and amyotrophic lateral sclerosis (ALS). The 
involvement of VDAC in numerous pathological 
conditions may result from disturbed VDAC function 
in energy production, metabolite cross-talk between the 
cytosol and the mitochondria, or apoptosis regulation. 
Muscular and myocardial diseases 
Note 
In a rabbit model for myocardial ischemia and 
reperfusion, it was demonstrated that the p38 MAPK 
inhibitor, PD169316, significantly reduced p38-
mediated phosphorylation of VDAC1, implicating 
VDAC1 in myocardial ischemia and reperfusion. 
VDAC and reagent toxicity 
Note 
ROS are known to activate apoptosis. In addition, ROS 
appears to activate VDAC. Furanonaphthoquinones 
(FNQs) were proposed to induce apoptosis via ROS. 
The ROS production and the anti-cancer activity of 
FNQs were increased upon VDAC1 overexpression 
and decreased upon silencing VDAC1 expression by 
siRNA. 
There are other chemicals that directly interact with and 
modify VDAC's activity. G3139 (oblimersen), an 18-
mer phosphorothioate anti-sense oligonucleotide 
targeted to the initiation codon region of Bcl-2 mRNA, 
directly binds and reduces the channel conductance of 
bilayer-reconstituted VDAC. Avicins represent a novel 
class of plant stress metabolites that exhibit cytotoxic 
activity in tumor cells, as well as anti-inflammatory and 
anti-oxidant properties capable of perturbing 
mitochondrial function and initiating apoptosis in 
tumor cells. Fluoxetine (Prozac), a clinically-used anti-
depressant compound which acts on multiple 
transporters and channels, enhanced cell proliferation 
and prevented or enhanced apoptosis in various cell 
lines. Fluoxetine was shown to interact directly with 
VDAC and inhibit apoptosis. Cisplatin is a widely used 
anti-cancer drug which acts by inducing apoptosis. 
Cisplatin binds and modulates VDAC's activity (Yang 
et al., 2006) to modulate VDAC1 activity. Acrolein (2-
propen-1-al), the most reactive of the α,β-unsaturated 
aldehydes and a toxic compound. VDAC was recently 
identified as a selectively oxidized target in the AD 
brain, being significantly carbonylated by acrolein. 
Endostatin (ES) has been shown to promote the  
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permeability transition pore (PTP) opening via VDAC. 
Silencing VDAC1 expression by siRNA attenuates ES-
induced apoptosis, while overexpression of VDAC1 
enhances the sensitivity of endothelial cells to ES. 
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